Cargando…

The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial

BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kangwana, Beth P., Kedenge, Sarah V., Noor, Abdisalan M., Alegana, Victor A., Nyandigisi, Andrew J., Pandit, Jayesh, Fegan, Greg W., Todd, James E., Brooker, Simon, Snow, Robert W., Goodman, Catherine A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104978/
https://www.ncbi.nlm.nih.gov/pubmed/21655317
http://dx.doi.org/10.1371/journal.pmed.1000437
_version_ 1782204660017266688
author Kangwana, Beth P.
Kedenge, Sarah V.
Noor, Abdisalan M.
Alegana, Victor A.
Nyandigisi, Andrew J.
Pandit, Jayesh
Fegan, Greg W.
Todd, James E.
Brooker, Simon
Snow, Robert W.
Goodman, Catherine A.
author_facet Kangwana, Beth P.
Kedenge, Sarah V.
Noor, Abdisalan M.
Alegana, Victor A.
Nyandigisi, Andrew J.
Pandit, Jayesh
Fegan, Greg W.
Todd, James E.
Brooker, Simon
Snow, Robert W.
Goodman, Catherine A.
author_sort Kangwana, Beth P.
collection PubMed
description BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3–59 months. METHODS AND FINDINGS: We used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL. CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07. Please see later in the article for the Editors' Summary
format Text
id pubmed-3104978
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31049782011-06-08 The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial Kangwana, Beth P. Kedenge, Sarah V. Noor, Abdisalan M. Alegana, Victor A. Nyandigisi, Andrew J. Pandit, Jayesh Fegan, Greg W. Todd, James E. Brooker, Simon Snow, Robert W. Goodman, Catherine A. PLoS Med Research Article BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3–59 months. METHODS AND FINDINGS: We used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL. CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07. Please see later in the article for the Editors' Summary Public Library of Science 2011-05-31 /pmc/articles/PMC3104978/ /pubmed/21655317 http://dx.doi.org/10.1371/journal.pmed.1000437 Text en Kangwana et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kangwana, Beth P.
Kedenge, Sarah V.
Noor, Abdisalan M.
Alegana, Victor A.
Nyandigisi, Andrew J.
Pandit, Jayesh
Fegan, Greg W.
Todd, James E.
Brooker, Simon
Snow, Robert W.
Goodman, Catherine A.
The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title_full The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title_fullStr The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title_full_unstemmed The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title_short The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
title_sort impact of retail-sector delivery of artemether–lumefantrine on malaria treatment of children under five in kenya: a cluster randomized controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104978/
https://www.ncbi.nlm.nih.gov/pubmed/21655317
http://dx.doi.org/10.1371/journal.pmed.1000437
work_keys_str_mv AT kangwanabethp theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT kedengesarahv theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT noorabdisalanm theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT aleganavictora theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT nyandigisiandrewj theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT panditjayesh theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT fegangregw theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT toddjamese theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT brookersimon theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT snowrobertw theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT goodmancatherinea theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT kangwanabethp impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT kedengesarahv impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT noorabdisalanm impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT aleganavictora impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT nyandigisiandrewj impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT panditjayesh impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT fegangregw impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT toddjamese impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT brookersimon impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT snowrobertw impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial
AT goodmancatherinea impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial